Frances A. Shepherd

Research interests

Publications

• Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2304594

• CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.02219

• Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

  JAMA Oncology · 2020 · https://doi.org/10.1001/jamaoncol.2020.0237

• Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.08.2100

• Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2027071

• Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

  Journal of Thoracic Oncology · 2018 · 10.1016/j.jtho.2018.05.030

• EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.18.01585

• CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx820

• Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

  Nature Genetics · 2017 · https://doi.org/10.1038/ng.3892

• Uncommon EGFR mutations in advanced non-small cell lung cancer

  Lung Cancer · 2017 · https://doi.org/10.1016/j.lungcan.2017.04.016

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1612674

• Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30508-3

• Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

  Genome Medicine · 2016 · https://doi.org/10.1186/s13073-016-0364-2

• Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients

  Journal of Thoracic Oncology · 2013 · https://doi.org/10.1097/jto.0000000000000042

• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70510-2

• Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.42.6932

• Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer

  Proceedings of the National Academy of Sciences · 2011 · https://doi.org/10.1073/pnas.1014506108

• EGFR Mutations and Lung Cancer

  Annual Review of Pathology Mechanisms of Disease · 2011 · 10.1146/annurev-pathol-011110-130206

• Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.4325

• Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.24.0333

• Lung cancer susceptibility locus at 5p15.33

  Nature Genetics · 2008 · https://doi.org/10.1038/ng.254

• Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.13.9030

• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)61758-4

• Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

  Nature Medicine · 2008 · https://doi.org/10.1038/nm.1790

• Characterizing the cancer genome in lung adenocarcinoma

  Nature · 2007 · 10.1038/nature06358

• Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.12.0352

• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

  New England Journal of Medicine · 2005 · 10.1056/nejmoa050736

• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa050753

• Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043623

• Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.08.163

• Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.

  PubMed · 2002

• Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

  Journal of Clinical Oncology · 2000 · https://doi.org/10.1200/jco.2000.18.10.2095

• Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

  European Journal of Cancer · 1996 · https://doi.org/10.1016/0959-8049(95)00444-0

Current projects

No projects listed.